PMID- 23673443
OWN - NLM
STAT- MEDLINE
DCOM- 20130827
LR  - 20220318
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 72
IP  - 1
DP  - 2013 Jul
TI  - HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after 
      first-line trastuzumab plus taxane chemotherapy in patients with HER2 
      fluorescence in situ hybridization-positive metastatic breast cancer.
PG  - 109-15
LID - 10.1007/s00280-013-2174-1 [doi]
AB  - PURPOSE: This study aimed to elucidate the clinical implication of human 
      epidermal growth factor receptor 2/centromeric probe for chromosome 17 
      (HER2/CEP17) ratio and HER2 immunohistochemistry (IHC) results in patients with 
      HER2 fluorescence in situ hybridization (FISH)-positive metastatic breast cancer 
      (MBC) who received first-line trastuzumab plus taxane chemotherapy. METHODS: 
      Using clinical data of patients with HER2 FISH-positive MBC who received 
      first-line trastuzumab plus taxane chemotherapy, we analyzed the clinical outcome 
      according to the HER2/CEP17 ratio and HER2 IHC analysis. RESULTS: Fifty-two women 
      were analyzed. The median age was 50 years (range 27-69 years). Patients with a 
      HER2/CEP17 ratio >/=3.0 had significantly longer progression-free survival (PFS) 
      (17.2 vs. 7.4 months; p = 0.002) with a tendency toward higher response rate (RR) 
      (p = 0.325) and longer overall survival (OS) (p = 0.129). Patients with HER2 IHC 
      1+ had significantly shorter OS (14.0 vs. 42.4 months; p = 0.013) along with a 
      tendency toward lower RR (p = 0.068) and shorter PFS (p = 0.220). In the 
      multivariate analysis, HER2/CEP17 ratio <3.0 (p = 0.004) and Eastern Cooperative 
      Oncology Group (ECOG) PS 2 (p = 0.015) were significant factors for shorter PFS, 
      and HER2 IHC 1+ (p = 0.015) and ECOG PS 2 (p = 0.036) were significant factors 
      for poor OS. CONCLUSIONS: Our data support that HER2/CEP17 ratios and HER2 IHC 
      scores may predict clinical outcome after first-line trastuzumab plus taxane 
      chemotherapy in patients with HER2 FISH-positive MBC.
FAU - Kim, Ji-Won
AU  - Kim JW
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea.
FAU - Kim, Jee Hyun
AU  - Kim JH
FAU - Im, Seock-Ah
AU  - Im SA
FAU - Kim, Yu Jung
AU  - Kim YJ
FAU - Han, Hye-Suk
AU  - Han HS
FAU - Kim, Jin-Soo
AU  - Kim JS
FAU - Lee, Kyung-Hun
AU  - Lee KH
FAU - Kim, Tae-Yong
AU  - Kim TY
FAU - Han, Sae-Won
AU  - Han SW
FAU - Jeon, Yoon Kyung
AU  - Jeon YK
FAU - Oh, Do-Youn
AU  - Oh DY
FAU - Kim, Tae-You
AU  - Kim TY
FAU - Park, In Ae
AU  - Park IA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130515
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Taxoids)
RN  - 1605-68-1 (taxane)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Antineoplastic Agents/administration & dosage/therapeutic use
MH  - *Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Biomarkers, Tumor/metabolism
MH  - Bone Neoplasms/diagnosis/drug therapy/secondary
MH  - Breast Neoplasms/diagnosis/*drug therapy/metabolism/pathology
MH  - Bridged-Ring Compounds/administration & dosage/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/diagnosis/drug therapy/secondary
MH  - Lymphatic Metastasis/diagnosis
MH  - Mammary Glands, Human/*drug effects/metabolism/pathology
MH  - Middle Aged
MH  - Neoplasm Proteins/*metabolism
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Taxoids/administration & dosage/*therapeutic use
MH  - Trastuzumab
EDAT- 2013/05/16 06:00
MHDA- 2013/08/28 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/11/26 00:00 [received]
PHST- 2013/04/19 00:00 [accepted]
PHST- 2013/05/16 06:00 [entrez]
PHST- 2013/05/16 06:00 [pubmed]
PHST- 2013/08/28 06:00 [medline]
AID - 10.1007/s00280-013-2174-1 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 
      10.1007/s00280-013-2174-1. Epub 2013 May 15.